UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?

BMC cancer, 2022-03, Vol.22 (1), p.323-323, Article 323

2022

Link zum Volltext

Verfügbarkeit prüfen

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study

BMC cancer, 2022-10, Vol.22 (1), p.1-1047, Article 1047

2022

Link zum Volltext

Verfügbarkeit prüfen

High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study

Journal of translational medicine, 2021-02, Vol.19 (1), p.92-92, Article 92

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer

Thoracic cancer, 2023-02, Vol.14 (5), p.442-449

2023

Link zum Volltext

Verfügbarkeit prüfen

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study

BMC cancer, 2017-05, Vol.17 (1), p.302-302, Article 302

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation

Thoracic cancer, 2021-02, Vol.12 (3), p.329-338

2021

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents

Cancer chemotherapy and pharmacology, 2015-10, Vol.76 (4), p.771-776

2015

Link zum Volltext

Verfügbarkeit prüfen

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease

BMC cancer, 2014-07, Vol.14 (1), p.508-508, Article 508

2014

Link zum Volltext

Verfügbarkeit prüfen

EOP10. Outcomes associated with immune-related adverse events in non-small cell lung cancer treated with pembrolizumab plus chemotherapy

Annals of The Japanese Respiratory Society, 2022-04, Vol.11 (suppl), p.321-321

2022

Link zum Volltext

Verfügbarkeit prüfen

Cerebral infarction in advanced non-small cell lung cancer: a case control study

BMC cancer, 2016-03, Vol.16 (203), p.203-203, Article 203

2016

Link zum Volltext

Verfügbarkeit prüfen

The outcome of patients with resected clinical N3 or M1 lung cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e18527-e18527

2014

Link zum Volltext

Verfügbarkeit prüfen

Vulnerability Exploiting SMS Push Notifications

2021 16th Asia Joint Conference on Information Security (AsiaJCIS), 2021, p.23-30

2021

Link zum Volltext

Verfügbarkeit prüfen

The risk factors for severe adverse events of chemotherapy for advanced non-small cell lung cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e19129-e19129

2014

Link zum Volltext

Verfügbarkeit prüfen

EPD14-1 The Role of CD44 in the Regulation of Cancer Stem Cell Related Factors in Non-Small Cell Lung Cancer

Annals of The Japanese Respiratory Society, 2018-03, Vol.7 (suppl), p.361-361

2018

Link zum Volltext

Verfügbarkeit prüfen

EPD14-2. Role of Ubiquitin Ligase FBXW7 in the Quiescent Cancer Stem Cells in the Gefitinib Resistance in Non-small Cell Lung Cancer

Annals of The Japanese Respiratory Society, 2018-03, Vol.7 (suppl), p.361-361

2018

Link zum Volltext

Verfügbarkeit prüfen

EPD1-5 Serum surfactant proteins-D level as a predictor of prognosis of interstitial lung disease induced by anticancer-agents in advanced lung cancer

Annals of The Japanese Respiratory Society, 2017-03, Vol.6 (suppl), p.335-335

2017

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for serious adverse events due to cytotoxic chemotherapy for advanced non-small cell lung cancer

Cancer treatment and research communications, 2016, Vol.9, p.106-110

2016

Link zum Volltext

Verfügbarkeit prüfen

EPD5-5 Inhibitory effect of Dasatinib on pulmonary fibrosis in mice

Annals of The Japanese Respiratory Society, 2015-03, Vol.4 (suppl), p.345-345

2015

Link zum Volltext

Verfügbarkeit prüfen

EPD13-6 Two cases of S-1-induced interstitial lung disease

Annals of The Japanese Respiratory Society, 2015-03, Vol.4 (suppl), p.354-354

2015

Link zum Volltext

Verfügbarkeit prüfen

EPD13-4 Advanced non-small cell lung cancer with cerebral infarction

Annals of The Japanese Respiratory Society, 2015-03, Vol.4 (suppl), p.354-354

2015

Link zum Volltext

Verfügbarkeit prüfen

EPD8-3 Pulmonary toxicity in non-small cell lung cancer patients treated with taxotere and one-taxotere

Annals of The Japanese Respiratory Society, 2014-03, Vol.3 (suppl), p.351-351

2014

Link zum Volltext

Verfügbarkeit prüfen

Flat thin polarizer-lens based on multiple resonance behavior

2010 IEEE Antennas and Propagation Society International Symposium, 2010, p.1-4

2010

Link zum Volltext
IEEE_Xplore

KLF4 is required for suppression of histamine synthesis by polyamines during bone marrow-derived mast cell differentiation

PloS one, 2020-02, Vol.15 (2), p.e0229744-e0229744

2020

Link zum Volltext

Verfügbarkeit prüfen

Two new lignans and melanogenesis inhibitors from Schisandra nigra

Journal of natural medicines, 2016-07, Vol.70 (3), p.460-466

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-01-15: Monitoring of CDK4/6 inhibitor treatment response through blood liquid biopsy in metastatic breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P5-P5-01-15

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(27)
Tagungsberichte
(2)

Sprache

Englisch
(20)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Life Sciences & Biomedicine
(10)
Chemotherapy
(8)
Humans
(7)
Lung Cancer
(7)
Oncology
(7)
Aged
(5)
Cancer Therapies
(5)
Female
(5)
Lung Neoplasms - Drug Therapy
(5)
Male
(5)
Non-Small Cell Lung Cancer
(5)
Patients
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)
Lung Cancer, Non-Small Cell
(4)
Medical Prognosis
(4)
Middle Aged
(4)
Prognosis
(4)
Aged, 80 And Over
(3)
Apoptosis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study

High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study

Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation

Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease

EOP10. Outcomes associated with immune-related adverse events in non-small cell lung cancer treated with pembrolizumab plus chemotherapy

Cerebral infarction in advanced non-small cell lung cancer: a case control study

The outcome of patients with resected clinical N3 or M1 lung cancer

Vulnerability Exploiting SMS Push Notifications

The risk factors for severe adverse events of chemotherapy for advanced non-small cell lung cancer

EPD14-1 The Role of CD44 in the Regulation of Cancer Stem Cell Related Factors in Non-Small Cell Lung Cancer

EPD14-2. Role of Ubiquitin Ligase FBXW7 in the Quiescent Cancer Stem Cells in the Gefitinib Resistance in Non-small Cell Lung Cancer

EPD1-5 Serum surfactant proteins-D level as a predictor of prognosis of interstitial lung disease induced by anticancer-agents in advanced lung cancer

Risk factors for serious adverse events due to cytotoxic chemotherapy for advanced non-small cell lung cancer

EPD5-5 Inhibitory effect of Dasatinib on pulmonary fibrosis in mice

EPD13-6 Two cases of S-1-induced interstitial lung disease

EPD13-4 Advanced non-small cell lung cancer with cerebral infarction

EPD8-3 Pulmonary toxicity in non-small cell lung cancer patients treated with taxotere and one-taxotere

Flat thin polarizer-lens based on multiple resonance behavior

KLF4 is required for suppression of histamine synthesis by polyamines during bone marrow-derived mast cell differentiation

Two new lignans and melanogenesis inhibitors from Schisandra nigra

Abstract P5-01-15: Monitoring of CDK4/6 inhibitor treatment response through blood liquid biopsy in metastatic breast cancer

Suchergebnisse filtern